Transcept Aims To Refile Intermezzo Insomnia NDA In Late Q4 With Highway Driving Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved a resubmission plan that responds to concerns about inadvertent re-dosing and next-day driving impairment raised in an October "complete response" letter.
You may also be interested in...
Approval Delays For Transcept's Insomnia Drug Come At A Price; Milestone Payments At Stake
Transcept expects Purdue to pay a significantly lower approval milestone payment for Intermezzo given regulatory delays.
Approval Delays For Transcept's Insomnia Drug Come At A Price; Milestone Payments At Stake
Transcept expects Purdue to pay a significantly lower approval milestone payment for Intermezzo given regulatory delays.
Medication Errors: FDA Renews Focus On Drug Packaging As Part Of Prevention Campaign
June workshop is first step in development of a guidance addressing what drug developers can do to reduce mistakes.